Updated Results for PACIFIC Trial Establish New Standard of Care in Lung Cancer
David Spigel, MD, medical oncologist and Chief Scientific Officer at Sarah Cannon Research Institute, discusses the updated results for the PACIFIC trial, a randomized phase III trial investigating the addition of durvalumab (Imfinzi) to chemoradiation versus placebo in patients with unresectable stage III lung cancer.
David Spigel, MD, medical oncologist and Chief Scientific Officer at Sarah Cannon Research Institute, discusses the updated results for the PACIFIC trial, a randomized phase III trial investigating the addition of durvalumab (Imfinzi) to chemoradiation versus placebo in patients with unresectable stage III lung cancer.
In this trial, patients with unresectable phase III disease, either squamous or nonsquamous, and regardless of PD-L1 expression, were given chemoradiation. They were then randomized to receive durvalumab every 2 weeks for up to 1 year. The primary endpoint of this trial was progression-free survival (PFS) with a secondary endpoint of overall survival (OS).
Enasidenib Shows Promise as Post-Transplant Maintenance in IDH2-Mutated AML
January 7th 2025Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic stem cell transplant maintenance therapy for IDH2-mutated acute myeloid leukemia treatment.
Read More
